Sponsored Article Image

A message from Exosens

High temperature fission chambers engineered for AMR/SMR safety and performance

Learn More

Research & Applications

Astatine-211 targets blood-borne cancers in Seattle clinical trials

September 13, 2022, 9:30AMNuclear News
A clinical dose of At-211 is prepared at the University of Washington for use in a Fred Hutchison Cancer Center clinical trial. (Photo: UW/Don Hamlin)

Scientists in the Departments of Radiation Oncology and Medicine at the University of Washington (UW) and Fred Hutchinson Cancer Center (Fred Hutch) are directly targeting cancerous cells traveling through patients’ bloodstreams with diseases such as leukemia and lymphoma using an intravenous injection of the radioactive isotope astatine-211 (At-211). The work, its challenges, and its promise were described in a recent news release from the National Isotope Development Center (NIDC), which is managed by the Department of Energy’s Isotope Program.

To continue reading, log in or create a free account!
Sponsored Article Image

A message from Westinghouse

Supercharging the Nuclear Industry with Westinghouse AI

Learn More

Related Articles

Deep Fission raises $30M in financing

September 8, 2025, 3:13PMNuclear News

Since the Department of Energy kicked off a 10-company race with its Nuclear Reactor Pilot Program to bring test reactors on line by July 4, 2026, the industry has been waiting for new...

Aalo breaks ground in Idaho

September 3, 2025, 7:01AMNuclear News

Eight days after Aalo Atomics released the details of its securing of $100 million in Series B funding, the company announced that it has broken ground on the 10-MWe Aalo-X. Sited in the...